For the first time in the company’s history, Kalms Consulting was on a roadshow to China mid of October. Starting in Shanghai and continuing to Beijing, we met with various important players on the Chinese med tech and life science market, including distributors and investors.


The Chinese healthcare market for European and US med tech and life science companies

The Chinese healthcare market is of growing importance and (by overall volume) already on the third place worldwide. Being present on this market can significantly increase revenue and company valuation. With the right partner in place market access in China will be successful and the time needed for regulatory obligations can be minimized.

There is a fast-growing interest of strong and countrywide present distributors for new and innovative products – capital goods as well as expensive disposables and consumables. Various kinds of agreements, including risk sharing and market development activities executed by the distributor are possible.

Significant interest of Chinese investors in European and US med tech and life science companies

The interest of Chinese investors in med tech and life-science companies in Europe and in the US, is tremendous. Investments can range from minority to majority or even acquisition of the entire company. While in the past investors tend to move IP and infrastructure to China, this has significantly changed in the past years. In most cases the European / US business remains unchanged but new sales channels in China and other countries with strong links to China become accessible.

Our roadshow to China was in collaboration with Taylor Wessing, a full-service international law firm, working with clients in the world’s most dynamic industries. Taylor Wessing attorneys can support our clients with protecting their IP and all needed contracts and legal advice when entering the Chinese market.

In case of any interest in the Chinese market you are very welcome to contact me.

Stephan Binder